BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35658892)

  • 1. A gene prognostic index from cellular senescence predicting metastasis and radioresistance for prostate cancer.
    Feng D; Li D; Shi X; Xiong Q; Zhang F; Wei Q; Yang L
    J Transl Med; 2022 Jun; 20(1):252. PubMed ID: 35658892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cellular senescence-related gene prognostic index for biochemical recurrence and drug resistance in patients with prostate cancer.
    Feng D; Shi X; You J; Xiong Q; Zhu W; Wei Q; Yang L
    Am J Cancer Res; 2022; 12(8):3811-3828. PubMed ID: 36119834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An autophagy-related gene prognostic index predicting biochemical recurrence, metastasis, and drug resistance for prostate cancer.
    Zhu WZ; Feng DC; Xiong Q; Shi X; Zhang FC; Wei Q; Yang L
    Asian J Androl; 2023; 25(2):208-216. PubMed ID: 36412461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients.
    Feng D; Zhu W; You J; Shi X; Han P; Wei W; Wei Q; Yang L
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Gene Prognostic Index Associated With Epithelial-Mesenchymal Transition Predicting Biochemical Recurrence and Tumor Chemoresistance for Prostate Cancer.
    Feng D; Shi X; Xiong Q; Zhang F; Li D; Yang L
    Front Oncol; 2021; 11():805571. PubMed ID: 35096608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of senescence-related molecular subtypes and key genes for prostate cancer.
    Feng DC; Zhu WZ; Shi X; Xiong Q; You J; Wei Q; Yang L
    Asian J Androl; 2023; 25(2):223-229. PubMed ID: 36124532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing an immune-related gene prognostic index associated with progression and providing new insights into the tumor immune microenvironment of prostate cancer.
    Feng D; Zhang F; Li D; Shi X; Xiong Q; Wei Q; Yang L
    Immunology; 2022 Jun; 166(2):197-209. PubMed ID: 35271752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Senescence-associated secretory phenotype constructed detrimental and beneficial subtypes and prognostic index for prostate cancer patients undergoing radical prostatectomy.
    Feng D; Wang J; Li D; Wu R; Wei W; Zhang C
    Discov Oncol; 2023 Aug; 14(1):155. PubMed ID: 37624511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Ferroptosis-Related Gene Prognostic Index Associated With Biochemical Recurrence and Radiation Resistance for Patients With Prostate Cancer Undergoing Radical Radiotherapy.
    Feng D; Shi X; Xiong Q; Zhang F; Li D; Wei W; Yang L
    Front Cell Dev Biol; 2022; 10():803766. PubMed ID: 35223835
    [No Abstract]   [Full Text] [Related]  

  • 10. Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer.
    Ramalho-Carvalho J; Graça I; Gomez A; Oliveira J; Henrique R; Esteller M; Jerónimo C
    J Hematol Oncol; 2017 Feb; 10(1):43. PubMed ID: 28166834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer.
    Arnold Egloff SA; Du L; Loomans HA; Starchenko A; Su PF; Ketova T; Knoll PB; Wang J; Haddad AQ; Fadare O; Cates JM; Lotan Y; Shyr Y; Clark PE; Zijlstra A
    Oncotarget; 2017 Jan; 8(1):722-741. PubMed ID: 27894096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Energy Metabolism-Related Gene Prognostic Index Predicts Biochemical Recurrence for Patients With Prostate Cancer Undergoing Radical Prostatectomy.
    Feng D; Shi X; Zhang F; Xiong Q; Wei Q; Yang L
    Front Immunol; 2022; 13():839362. PubMed ID: 35280985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
    Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
    Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of senescence-related lncRNA prognostic index correlating with prognosis and radiosensitivity in prostate cancer patients.
    Feng D; Li L; Shi X; Zhu W; Wang J; Wu R; Li D; Wei W; Han P
    Aging (Albany NY); 2023 Sep; 15(18):9358-9376. PubMed ID: 37742230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone.
    Hansen AG; Arnold SA; Jiang M; Palmer TD; Ketova T; Merkel A; Pickup M; Samaras S; Shyr Y; Moses HL; Hayward SW; Sterling JA; Zijlstra A
    Cancer Res; 2014 Mar; 74(5):1404-15. PubMed ID: 24385212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic risk analysis related to radioresistance genes in colorectal cancer.
    Qin H; Zhang H; Li H; Xu Q; Sun W; Zhang S; Zhang X; Zhu S; Wang H
    Front Oncol; 2022; 12():1100481. PubMed ID: 36741692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.
    Feng D; Xiong Q; Zhang F; Shi X; Xu H; Wei W; Ai J; Yang L
    Front Immunol; 2022; 13():777724. PubMed ID: 35154101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer.
    Liu B; Li X; Li J; Jin H; Jia H; Ge X
    Dis Markers; 2020; 2020():8860788. PubMed ID: 33101546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.